HER2-negative Breast Cancer Clinical Trials in Denver, Colorado

4 studies are recruiting for her2-negative breast cancer in Denver, Colorado right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Rocky Mountain Cancer Center, Denver, Colorado

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

2. BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

   This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growt…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado

   Locations

   62 in total

   Run by

   BeOne Medicines

   See if you can join NCT06120283 on ClinicalTrials.gov

3. A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

   A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dren Investigational Site, Denver, Colorado

   Locations

   10 in total

   Run by

   Dren Bio

   See if you can join NCT06999187 on ClinicalTrials.gov

4. First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

   This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, cataly…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HealthONE, Denver, Colorado

   Locations

   37 in total

   Run by

   Relay Therapeutics, Inc.

   See if you can join NCT05216432 on ClinicalTrials.gov